Compare GOGO & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOGO | EDIT |
|---|---|---|
| Founded | 1991 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 461.2M | 432.8M |
| IPO Year | 2011 | 2016 |
| Metric | GOGO | EDIT |
|---|---|---|
| Price | $3.35 | $2.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $15.00 | $5.30 |
| AVG Volume (30 Days) | 2.4M | ★ 3.7M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $910,491,000.00 | $31,937,000.00 |
| Revenue This Year | $3.68 | N/A |
| Revenue Next Year | $3.60 | N/A |
| P/E Ratio | $33.10 | ★ N/A |
| Revenue Growth | 104.74 | ★ 132.64 |
| 52 Week Low | $3.23 | $1.66 |
| 52 Week High | $16.82 | $4.54 |
| Indicator | GOGO | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 35.26 | 50.25 |
| Support Level | $3.29 | $2.47 |
| Resistance Level | $4.92 | $3.27 |
| Average True Range (ATR) | 0.27 | 0.22 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 10.81 | 52.56 |
Gogo Inc is a broadband connectivity service for the business aviation market. It provides a customizable suite of smart cabin systems for integrated connectivity, inflight entertainment, and voice solutions. It generates two types of revenue: service revenue consists of monthly subscription and usage fees paid by aircraft owners and operators for telecommunication, data, and in-flight entertainment services, and equipment revenue consists of proceeds from the sale of ATG and narrowband satellite connectivity equipment and is recognized when control of the equipment is transferred to OEMs and dealers, which generally occurs when the equipment is shipped. Geographically, it operates in United States; and International as well.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.